231 - 236 out of 236Page size: 10
  1. 2014

  2. Anxiolytic drug discovery: What are the novel approaches and how can we improve them

    Stewart, A. M. & Kalueff, A. V., Jan 2014, In: Expert Opinion on Drug Discovery. 9, 1, p. 15-26 12 p.

    Research output: Contribution to journal › Review article › peer-review

  3. Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD)

    Nguyen, M., Roth, A., Kyzar, E. J., Poudel, M. K., Wong, K., Stewart, A. M. & Kalueff, A. V., Jan 2014, In: Neurochemistry International. 66, 1, p. 15-26 12 p.

    Research output: Contribution to journal › Review article › peer-review

  4. Rethinking CNS disorders: Time for new drug targets?

    Kalueff, A. V., Stewart, A. M. & Gottesman, I. I., 2014, In: Trends in Pharmacological Sciences. 35, 10, p. 491-492 2 p.

    Research output: Contribution to journal › Letter › peer-review

  5. Testing anxiolytic drugs in the C57BL/6J mouse strain

    Kalueff, A. V. & Nguyen, M., 2014, In: Journal of Pharmacological and Toxicological Methods. 69, 2, p. 205-207 3 p.

    Research output: Contribution to journal › Letter › peer-review

  6. 2013

  7. Controlled substances and innovation of biomedicine: A preclinical perspective

    Stewart, A. M. & Kalueff, A. V., Dec 2013, In: Nature Reviews Neuroscience. 14, 12, p. 877 1 p.

    Research output: Contribution to journal › Letter › peer-review

  8. Developing 'integrative' zebrafish models of behavioral and metabolic disorders

    Nguyen, M., Yang, E., Neelkantan, N., Mikhaylova, A., Arnold, R., Poudel, M. K., Stewart, A. M. & Kalueff, A. V., 1 Nov 2013, In: Behavioural Brain Research. 256, p. 172-187 16 p.

    Research output: Contribution to journal › Review article › peer-review

Previous 1...20 21 22 23 24 Next

ID: 195833